Literature DB >> 26601627

The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment.

Cristina Margini1,2, Jean F Dufour1,2.   

Abstract

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. An increasing number of reports describe HCC in the setting of obesity and diabetes, two major risk factors for non-alcoholic fatty liver disease (NAFLD). The increasing incidence of these conditions and the emerging evidence of HCC in non-cirrhotic NAFLD prioritize a better understanding of NAFLD-related HCC epidemiology and pathogenesis in order to target screening policies and develop preventive-therapeutic strategies. In this review, we focus on the epidemiological impact of this condition, suggesting a possible link between HCC in cryptogenic cirrhosis and NAFLD. Furthermore, we analyse the suggested pathogenic mechanisms and the possible preventive-therapeutic strategies.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  HCC; NAFLD; diabetes; obesity

Mesh:

Year:  2015        PMID: 26601627     DOI: 10.1111/liv.13031

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  71 in total

Review 1.  The contrasting roles of inflammasomes in cancer.

Authors:  Qin He; Yu Fu; Dean Tian; Wei Yan
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

Review 2.  Gastrointestinal Complications of Obesity.

Authors:  Michael Camilleri; Harmeet Malhi; Andres Acosta
Journal:  Gastroenterology       Date:  2017-02-10       Impact factor: 22.682

3.  NOD1 inhibits proliferation and enhances response to chemotherapy via suppressing SRC-MAPK pathway in hepatocellular carcinoma.

Authors:  Xiaomin Ma; Yumin Qiu; Lihui Zhu; Yunxue Zhao; Yueke Lin; Dapeng Ma; Zhenzhi Qin; Caiyu Sun; Xuecheng Shen; Tao Li; Lihui Han
Journal:  J Mol Med (Berl)       Date:  2019-12-23       Impact factor: 4.599

Review 4.  Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD.

Authors:  Helen L Reeves; Marco Y W Zaki; Christopher P Day
Journal:  Dig Dis Sci       Date:  2016-02-26       Impact factor: 3.199

5.  Short- and Long-Term Outcomes of Liver Resection for Intrahepatic Cholangiocarcinoma Associated with the Metabolic Syndrome.

Authors:  Christian Hobeika; François Cauchy; Nicolas Poté; Pierre-Emmanuel Rautou; François Durand; Olivier Farges; Safi Dokmak; Valérie Vilgrain; Maxime Ronot; Valérie Paradis; Olivier Soubrane
Journal:  World J Surg       Date:  2019-08       Impact factor: 3.352

Review 6.  Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease.

Authors:  Alessandro Mantovani; Giovanni Targher
Journal:  Ann Transl Med       Date:  2017-07

Review 7.  New insights into BMP9 signaling in liver diseases.

Authors:  Qian-Qian Jiang; Bei-Bei Liu; Ke-Shu Xu
Journal:  Mol Cell Biochem       Date:  2021-05-21       Impact factor: 3.396

8.  NAFLD-Related Hepatocellular Carcinoma and the Four Horsemen of the Apocalypse.

Authors:  Jose D Debes; Andre Boonstra; Robert J de Knegt
Journal:  Hepatology       Date:  2020-03-04       Impact factor: 17.425

9.  Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI.

Authors:  Scott M Thompson; Ishan Garg; Eric C Ehman; Shannon P Sheedy; Candice A Bookwalter; Rickey E Carter; Lewis R Roberts; Sudhakar K Venkatesh
Journal:  Br J Radiol       Date:  2018-08-29       Impact factor: 3.039

Review 10.  Diagnosis of non-alcoholic fatty liver disease (NAFLD).

Authors:  Hannele Yki-Järvinen
Journal:  Diabetologia       Date:  2016-04-18       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.